Samuel T Chao1, Antonio De Salles2,3, Motohiro Hayashi4, Marc Levivier5, Lijun Ma6, Roberto Martinez7, Ian Paddick8, Jean Régis9, Samuel Ryu10, Ben J Slotman11, Arjun Sahgal12. 1. Department of Radiation Oncology, Rose Ella Burkhardt Brain Tumor and Neurooncology Center, Cleveland Clinic, Cleveland, Ohio. 2. Department of Neurosurgery, University of California Los Angeles, Los Angeles, California. 3. HCor Neuroscience, Sao Paulo, Brazil. 4. Department of Neurosurgery, Tokyo Women's Medical University, Tokyo, Japan. 5. Neurosurgery Service and Gamma Knife Center, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland. 6. Division Physics, Department of Radiation Oncology, University of California San Francisco, San Francisco, California. 7. Department Neurosurgery, Ruber International Hospital, Madrid, Spain. 8. Division Physics, National Hospital for Neurology and Neurosurgery, London, UK. 9. Department of Functional Neurosurgery, Timone University Hospital, Aix-Marseille University, Marseille, France. 10. Department of Radiation Oncology and Neurosurgery, Stony Brook University, Stony Brook, New York. 11. Department of Radiation Oncology, VU University Medical Center, Amsterdam, The Netherlands. 12. Department of Radiation Oncology, University of Toronto, Sunnybrook Odette Cancer Centre, Toronto, Ontario, Canada.
Abstract
BACKGROUND: Guidelines regarding stereotactic radiosurgery (SRS) for brain metastases are missing recently published evidence. OBJECTIVE: To conduct a systematic review and provide an objective summary of publications regarding SRS in managing patients with 1 to 4 brain metastases. METHODS: Using Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) guidelines, a systematic review was conducted using PubMed and Medline up to November 2016. A separate search was conducted for SRS for larger brain metastases. RESULTS: Twenty-seven prospective studies, critical reviews, meta-analyses, and published consensus guidelines were reviewed. Four key points came from these studies. First, there is no detriment to survival by withholding whole brain radiation (WBRT) in the upfront management of brain metastases with SRS. Second, while SRS on its own provides a high rate of local control (LC), WBRT may provide further increase in LC. Next, WBRT does provide distant brain control with less need for salvage therapy. Finally, the addition of WBRT does affect neurocognitive function and quality of life more than SRS alone. For larger brain metastases, surgical resection should be considered, especially when factoring lower LC with single-session radiosurgery. There is emerging data showing good LC and/or decreased toxicity with multisession radiosurgery. CONCLUSION: A number of well-conducted prospective and meta-analyses studies demonstrate good LC, without compromising survival, using SRS alone for patients with a limited number of brain metastases. Some also demonstrated less impact on neurocognitive function with SRS alone. Practice guidelines were developed using these data with International Stereotactic Radiosurgery Society consensus.
BACKGROUND: Guidelines regarding stereotactic radiosurgery (SRS) for brain metastases are missing recently published evidence. OBJECTIVE: To conduct a systematic review and provide an objective summary of publications regarding SRS in managing patients with 1 to 4 brain metastases. METHODS: Using Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) guidelines, a systematic review was conducted using PubMed and Medline up to November 2016. A separate search was conducted for SRS for larger brain metastases. RESULTS: Twenty-seven prospective studies, critical reviews, meta-analyses, and published consensus guidelines were reviewed. Four key points came from these studies. First, there is no detriment to survival by withholding whole brain radiation (WBRT) in the upfront management of brain metastases with SRS. Second, while SRS on its own provides a high rate of local control (LC), WBRT may provide further increase in LC. Next, WBRT does provide distant brain control with less need for salvage therapy. Finally, the addition of WBRT does affect neurocognitive function and quality of life more than SRS alone. For larger brain metastases, surgical resection should be considered, especially when factoring lower LC with single-session radiosurgery. There is emerging data showing good LC and/or decreased toxicity with multisession radiosurgery. CONCLUSION: A number of well-conducted prospective and meta-analyses studies demonstrate good LC, without compromising survival, using SRS alone for patients with a limited number of brain metastases. Some also demonstrated less impact on neurocognitive function with SRS alone. Practice guidelines were developed using these data with International Stereotactic Radiosurgery Society consensus.
Authors: Paolo Palmisciano; Ali S Haider; Kishore Balasubramanian; Randy S D'Amico; Alla Gabriella Wernicke Journal: J Neurooncol Date: 2022-06-13 Impact factor: 4.506
Authors: Assaf Berger; Ido Strauss; Shlomit Ben Moshe; Benjamin W Corn; Dror Limon; Nathan Shtraus; Tal Shahar; Andrew A Kanner Journal: J Neurooncol Date: 2018-08-04 Impact factor: 4.130
Authors: Andrei Mouraviev; Jay Detsky; Arjun Sahgal; Mark Ruschin; Young K Lee; Irene Karam; Chris Heyn; Greg J Stanisz; Anne L Martel Journal: Neuro Oncol Date: 2020-06-09 Impact factor: 12.300
Authors: John H Suh; Rupesh Kotecha; Samuel T Chao; Manmeet S Ahluwalia; Arjun Sahgal; Eric L Chang Journal: Nat Rev Clin Oncol Date: 2020-02-20 Impact factor: 66.675
Authors: Michael T Milano; Veronica L S Chiang; Scott G Soltys; Tony J C Wang; Simon S Lo; Alexandria Brackett; Seema Nagpal; Samuel Chao; Amit K Garg; Siavash Jabbari; Lia M Halasz; Melanie Hayden Gephart; Jonathan P S Knisely; Arjun Sahgal; Eric L Chang Journal: Neuro Oncol Date: 2020-12-18 Impact factor: 12.300
Authors: Linlin Xiao; Yvonne M Mowery; Brian G Czito; Yajing Wu; Guangbin Gao; Chang Zhai; Jianing Wang; Jun Wang Journal: Front Oncol Date: 2021-04-29 Impact factor: 6.244
Authors: Maria-Lisa Wilhelm; Mark K H Chan; Benedikt Abel; Florian Cremers; Frank-Andre Siebert; Stefan Wurster; David Krug; Robert Wolff; Jürgen Dunst; Guido Hildebrandt; Achim Schweikard; Dirk Rades; Floris Ernst; Oliver Blanck Journal: Strahlenther Onkol Date: 2020-06-25 Impact factor: 3.621
Authors: Michael H Soike; Ryan T Hughes; Michael Farris; Emory R McTyre; Christina K Cramer; J D Bourland; Michael D Chan Journal: Neurosurgery Date: 2019-03-01 Impact factor: 5.315